Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors

Exploratory Study to Evaluate the Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors

This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of Anti-CDH17 CAR-T cell injection in patients with CDH17-positive advanced malignant solid tumors.

Study Overview

• Status: Recruiting
• Conditions: CDH17-positive Advanced Malignant Solid Tumors
• Intervention / Treatment: Biological: Anti-CDH17 CAR-T cells

Detailed Description

This study will include two parts, dose escalation phase (accelerated titration and 3+3 design) followed by a dose expansion phase.

All eligible participants will receive a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by Anti-CDH17 CAR-T cell injection.

The dose escalation phase will determine the maximum tolerated dose (MTD) of Anti-CDH17 CAR-T cell injection. Additional patients will be enrolled in the dose expansion phase to further characterize the safety profile and evaluate the efficacy of Anti-CDH17 CAR-T cell injection, and establish recommended phase 2 dose (RP2D).

• Study Type: Interventional
• Enrollment (Estimated): 17
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Zhiguo Long; Phone Number: 18117253161; Email: zglong1976@126.com

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China
      • Recruiting
      • Shanghai Pudong Hospital
      • Contact: Zhiguo Long; Phone Number: 18117253161; Email: zglong1976@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. 18 to 70 years old (including cut-off value), gender is not limited.
2. Solid tumors that histological diagnosis of malignancy refractory to, or relapsing after standard therapy, including but not limited to colorectal cancer, gastric cancer, pancreatic cancer, biliary tract cancer.
3. At least one measurable lesion according to RECIST v1.1.
4. CDH17 should be positive confirmed by Immunohistochemistry/Immunocytochemistry (IHC/ICC) in tumor tissue samples.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
6. Life expectancy ≥ 3 months.
7. Organ function must meet protocol requirements
8. Female participants of childbearing potential must undergo a pregnancy test and the results must be negative. Female participants of childbearing potential or male participants whose sex partner has childbearing potential must be willing to use effective methods of contraception from screening period to at least 1 year after infusion.
9. Participants must be able to understand the protocol and be willing to enroll the study, sign the informed consent, and be able to comply with the study and follow-up procedures.

Exclusion Criteria:

1. Patients have received systemic therapy with cytotoxic chemicals, monoclonal antibodies, or immunotherapy within 4 weeks or 5 half-lives (which is shorter) prior to signing informed consent; Patients have received systemic glucocorticoids (prednisone at a dose of ≥10 mg per day or equivalent) or other immune-suppressive therapy within 2 weeks prior to signing informed consent; Patients have received systemic antitumor therapy with a biologic agent or other approved targeted small-molecule inhibitor within 1 week or five half-lives (which is shorter) prior to signing informed consent; Patients have received Chinese herbal medicine or Chinese patent medicine with anti-tumor indication within 1 week prior to signing informed consent.
2. Pregnant or lactating women.
3. Patients with hepatitis B surface antigen (HBsAg) positive. Patients who is hepatitis B core antibody (HBcAb) positive and the quantification of HBV DNA in peripheral blood is higher than the lower limit of detection. Patients who is hepatitis C virus (HCV) antibody positive and quantification of HCV DNA in peripheral blood is higher than the lower limit of detection. Patients with human immunodeficiency virus (HIV) antibody positive, or syphilis antibody positive.
4. The toxicities caused by the prior therapy (surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) have not recovered to grade 1 according to CTCAE, except for hair loss and peripheral sensory nerve disorders.
5. Have received any allogeneic tissue/organ transplantation (including bone marrow transplantation, stem cell transplantation, liver transplantation, kidney transplantation), except for the transplantation that does not require immunosuppressive therapy (such as: corneal transplantation, hair transplantation.)
6. Patients have received anti-CDH17 CAR-T cell therapy.
7. Patients who have history of major surgery and unrecovered severe trauma within 4 weeks prior to signing informed consent; or plan to have major surgery within 12 weeks of cell therapy.
8. Presence of known central nervous system metastases, but the following patients will be allowed: a) Asymptomatic brain metastases; b) Clinically stable (no radiographic progression within 4 weeks before apheresis and return of any neurologic symptoms to baseline), and with no need for corticosteroids or other treatment for brain metastases for ≥ 4 weeks.

9. Patients with clinically significant systemic disease (such as: severe active infection or significant cardiac, pulmonary, hepatic, nervous system, or other organ dysfunction) that evaluated by the investigator would impair the patients' ability to tolerate the treatments used in this study or significantly increase the risk of complications.

   • Uncontrolled severe active infection (sepsis, bacteremia, viremia, etc.);
   • Lung disease requiring systemic hormone therapy;
   • Congestive heart failure with New York Heart Association (NYHA) functional class > 1;
   • Clinically significant severe aortic stenosis and symptomatic mitral stenosis;
   • Electrocardiogram QTc > 450 msec or QTc > 480 msec in patients with bundle-branch block;
   • Uncontrolled clinically significant arrhythmia within 6 months prior to signing informed consent;
   • Acute coronary syndrome (such as: unstable angina, myocardial infarction) within 6 months prior to signing informed consent;
   • Drug-uncontrolled hypertension (systolic pressure ≥ 160 mmHg and/or diastolic pressure ≥ 100 mmHg) or pulmonary hypertension;
   • Cerebrovascular accident occurred within 6 months prior to signing informed consent, including transient ischemic attack (TIA), cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage;
   • A history of active, chronic, or recurrent (within 1 year prior to signing informed consent) severe autoimmune disease or immune-mediated disease requiring steroids or other immunosuppressive therapy, including but not limited to systemic lupus erythematosus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Hashimoto's thyroiditis, autoimmune thyroid disease, multiple sclerosis. Exceptions: hypothyroidism that can be controlled only by hormone replacement therapy, skin diseases (such as: vitiligo, psoriasis) that do not require systemic treatment, coeliac disease that has been controlled;
   • Any form of primary or secondary immunodeficiency, such as severe combined immunodeficiency (SCID);
   • Possibility of bleeding from esophageal or gastric varices evaluated by the investigator.
10. History of severe systemic hypersensitivity reaction to the drugs/ingredients [fludarabine, cyclophosphamide, dimethyl sulfoxide (DMSO), low molecular dextran, human serum albumin (HSA), etc.] used in this study.
11. Patients have received attenuated vaccine within 4 weeks prior to signing informed consent.
12. Patients have received other clinical trials within 4 weeks prior to signing informed consent.
13. History of another malignancy tumor within the previous five years, except for adequately treated non-melanoma skin cancer, carcinoma in situ of bladder, stomach, colon, cervix/dysplasia, melanoma, or breast.
14. History of neuropsychiatric diseases diagnosed by the ICD-11 criteria or evaluated by investigator, including but not limited to epilepsy, schizophrenia, dementia, drug and alcohol addictions.
15. For any other reasons, the patients are believed not suitable for participation in this study by investigators.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Anti-CDH17 CAR-T cells	Biological: Anti-CDH17 CAR-T cells; Anti-CDH17 CAR-T cell injection will be administered intravenously after lymphodepleting.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events (AEs)	Incidence and severity of adverse events.	2 years
Serious Adverse Events (SAEs)	Incidence and severity of serious adverse events.	2 years
Adverse Events of Special Interest (AESI)	Incidence and severity of adverse event of special interest.	2 years
Identification of Maximum Tolerated Dose (MTD) & Incidence of Dose-limiting Toxicities (DLTs)	Incidence and severity of dose-limiting toxicities (DLTs) following infusion of CAR-T cell injection, at each dose level tested in dose escalation phase.	4 weeks after the CAR-T cells infusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR)	The Objective Response Rate (ORR) is the percentage of participants who achieved Complete Response (CR) or Partial Response (PR) based on RECIST version 1.1.	2 years
Disease Control Rate (DCR)	Disease control rate (DCR) is the percentage of participants who achieved Complete Response (CR) or Partial Response (PR) or Stable disease (SD) based on RECIST version 1.1.	2 years
Progression-Free Survival (PFS)	PFS is defined as the time from CAR-T infusion to the date of the disease progression or death from any cause.	2 years
Overall Survival (OS)	OS is defined as the time from CAR-T infusion to the date of death due to any cause.	2 years
Anti-drug Antibodies	Number of participants with anti-drug antibodies.	2 years
Bio-distribution of CAR-T cells	CAR copies will be measured by qPCR to evaluate the expansion and persistence of CAR-T cells in vivo. Cmax, Tmax, AUC0-tlast and AUC0-inf of CAR copies will be analyzed.	2 years
Cytokine Level in Peripheral Blood	Level of cytokines (IL-2、IL-6、IL-8、IL-10、TNF-α and IFN-γ, etc.) in serum.	2 years

Collaborators and Investigators

• Sponsor: Shanghai Pudong Hospital
• Collaborators: UTC Therapeutics Inc.

Study record dates

Study Major Dates

• Study Start (Actual): July 8, 2024
• Primary Completion (Estimated): May 30, 2025
• Study Completion (Estimated): May 30, 2026

Study Registration Dates

• First Submitted: July 8, 2024
• First Submitted That Met QC Criteria: July 8, 2024
• First Posted (Actual): July 15, 2024

Study Record Updates

• Last Update Posted (Actual): July 15, 2024
• Last Update Submitted That Met QC Criteria: July 8, 2024
• Last Verified: July 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: Anti-CDH17 CAR-T cells

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No